Sanofi May Have Known About Ranitidine Being Inherently Carcinogenic
Zantac users that have developed cancer after using the heartburn and acid reflux medicine may have a good case
Friday, June 4, 2021 - People who have filed suit against Sanofi and GalaxoSmithKline accuse the companies of covering up what they knew for decades, that ranitidine (Zantac) is inherently unstable and degrades into N-nitrosodimethylamine (NDMA), a deadly carcinogen. More than 15 million people were taking Zantac regularly when it was recalled. Tens of millions of Americans may have exposed themselves to the risk of developing stomach, bladder, esophagus, colon, prostate, and breast cancer because Zantac‘s manufacturer hid the truth and put company profits ahead of their customer‘s health. Sanofi and GalaxoSmithKline are currently under investigation by the Department of Justice for lying to government regulators. People who were injured by Sanofi‘s negligence have filed lawsuits that could help them recover their past and future medical expenses and past and future lost income. Litigants could also receive a substantial lump sum jury award for punitive damages as jurors may be outraged at the company‘s reprehensible behavior. You should speak with a Zantac cancer attorney if you have been taking Zantac and developed cancer. Around 500 lawsuits have been grouped in MDL before U.S. District Judge Robin Rosenberg. New Mexico Attorney General Hector Balderas has filed a lawsuit against Sanofi and other ranitidine and Zantac sellers, alleging Sanofi covered up what they knew about Zantac potentially causing cancer. Plaintiff attorneys familiar with the Zantac cancer facts suspect that thousands of former Zantac users will come forward in the months to come and file similar complaints. Visit Zantac antacid cancer lawsuit to learn more.
The FDA pulled ranitidine off store shelves in the United States in April of 2020, and since that time, researchers have been studying how NDMA levels could have skyrocketed. It was first suspected that NDMA could develop as a result of being stored at higher then normal temperatures at retailers. Researchers also theorized that NDMA levels could escalate when the compound interacted with nitrates found in the stomach. The conclusion of online prescription drug testing pharmacy Valisure is that ranitidine is inherently unstable and naturally breaks down to become carcinogenic. Scientists at Valisure are particularly concerned about ranitidine because elevated levels of NDMA have been found in every brand and generic version of the chemical compound. Valisure, in conjunction with researchers at Memorial Sloan Kettering Cancer hospital in NY, has also studied a sampling of 10,000 individuals that have taken Zantac regularly for years and they have found, not surprisingly, that those people have many times more the risk of getting cancer than those who have not taken the heartburn medicine. "A study published online by the Journal of the American Medical Association on 29 January included in vitro tests with simulated gastric fluids and a cross-sectional evaluation of 10,347 cancer patients which found a ‘significant‘ association between the use of ranitidine and elevated diagnosis rates of breast, thyroid, bladder, and prostate cancers while finding an inverse association among other types of cancer," writes PharmaIntelligence.
